Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001683168-24-003883
Filing Date
2024-05-30
Accepted
2024-05-30 16:05:03
Documents
1
Group Members
PHARMACYTE BIOTECH, INC.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D pharm_sc13d.htm SC 13D 50511
  Complete submission text file 0001683168-24-003883.txt   52660
Mailing Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653
Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653 (917) 595.2850
PharmaCyte Biotech, Inc. (Filed by) CIK: 0001157075 (see all company filings)

EIN.: 621772151 | State of Incorp.: NV | Fiscal Year End: 0430
Type: SC 13D
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Subject) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88005 | Film No.: 241005153
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)